2023-2029 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Research & Trends Analysis Report
2023-2029 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Research & Trends Analysis Report
Insights into the Chronic Graft-versus-host Disease (cGVHD) Treatment Market include supply chain optimization, Chronic Graft-versus-host Disease (cGVHD) Treatment challenges, and growth forecasts segmented by region and service type.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
According to the latest research analysis,the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
China Chronic Graft-versus-host Disease (cGVHD) Treatment market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
The United States Chronic Graft-versus-host Disease (cGVHD) Treatment market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
In terms of type, Corticosteroids segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Hospitals Pharmacies has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.
The global key manufacturers of Chronic Graft-versus-host Disease (cGVHD) Treatment include Merck KGaA, Sanofi SA, Novartis AG, Bristol Myers Squibb, Pfizer, Roche Holding AG, Johnson & Johnson, Eli Lilly and Company and Abbott Laboratories, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive study of the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment.
Data-Driven Insights: Highlights from Our Report
(1) Global Chronic Graft-versus-host Disease (cGVHD) Treatment market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.
(2) Global Chronic Graft-versus-host Disease (cGVHD) Treatment market competitive situation, revenue and market share, from 2018 to 2022.
(3) China Chronic Graft-versus-host Disease (cGVHD) Treatment market competitive situation, revenue and market share, from 2018 to 2022.
(4) Global Chronic Graft-versus-host Disease (cGVHD) Treatment segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.
(5) Global Chronic Graft-versus-host Disease (cGVHD) Treatment segment by type and by application and regional segment by type and by application.
(6) Chronic Graft-versus-host Disease (cGVHD) Treatment industry supply chain, upstream, midstream and downstream analysis.
Breaking Down Market Segments by Region: A Deep Dive Analysis
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Understanding Market Segments by Type: A Comparative Analysis
Corticosteroids
mTOR Inhibitors
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Market Segmentation by Application: Dividing Key Markets and Identifying Opportunities
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Understanding Market Segments by Key Players: Insights and Opportunities
Merck KGaA
Sanofi SA
Novartis AG
Bristol Myers Squibb
Pfizer
Roche Holding AG
Johnson & Johnson
Eli Lilly and Company
Abbott Laboratories
Takeda Pharmaceutical Company
1 Market Overview
1.1 Product Overview and Scope of Chronic Graft-versus-host Disease (cGVHD) Treatment
1.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size and Forecast
1.3 China Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size and Forecast
1.4 China Market Percentage in Global
1.4.1 By Revenue, China Chronic Graft-versus-host Disease (cGVHD) Treatment Share in Global Market, 2018-2029
1.4.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size: China VS Global, 2018-2029
1.5 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Dynamics
1.5.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers
1.5.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints
1.5.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Trends
1.5.4 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Policy
2 Global Competitive Situation by Company
2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Company (2018-2023)
2.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)
2.3 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Concentration Ratio
2.4 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Mergers & Acquisitions, Expansion Plans
2.5 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Manufacturers Product Type
3 China Competitive Situation by Company
3.1 China Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Company (2018-2023)
3.2 China Chronic Graft-versus-host Disease (cGVHD) Treatment Chronic Graft-versus-host Disease (cGVHD) Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)
3.3 China Chronic Graft-versus-host Disease (cGVHD) Treatment, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)
4 Industry Chain Analysis
4.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Chain
4.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Upstream Analysis
4.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Midstream Analysis
4.4 Chronic Graft-versus-host Disease (cGVHD) Treatment Downstream Analysis
5 Sights by Type
5.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Classification
5.1.1 Corticosteroids
5.1.2 mTOR Inhibitors
5.1.3 Tyrosine Kinase Inhibitors
5.1.4 Monoclonal Antibodies
5.1.5 Others
5.2 By Type, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & CAGR, 2018 VS 2022 VS 2029
5.3 By Type, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue, 2018-2029
6 Sights by Application
6.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Segment by Application
6.1.1 Hospitals Pharmacies
6.1.2 Retail Pharmacies
6.1.3 Online Pharmacies
6.2 By Application, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018 VS 2022 VS 2029
7.2 By Region, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
7.3 North America
7.3.1 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & Forecasts, 2018-2029
7.3.2 By Country, North America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Market Share
7.4 Europe
7.4.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Market Share
7.6 South America
7.6.1 South America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Market Share
7.7 Middle East & Africa
8 Sights by Country Level
8.1 By Country, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size & CAGR，2018 VS 2022 VS 2029
8.2 By Country, Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.3 U.S.
8.3.1 U.S. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.3.2 By Company, U.S. Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.3.3 By Type, U.S. Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.3.4 By Application, U.S. Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.4.2 By Company, Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.4.3 By Type, Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.4.4 By Application, Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.5 China
8.5.1 China Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.5.2 By Company, China Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.5.3 By Type, China Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.5.4 By Application, China Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.6.2 By Company, Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.6.3 By Type, Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.6.4 By Application, Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.7.2 By Company, South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.7.3 By Type, South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.7.4 By Application, South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.8.2 By Company, Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.8.3 By Type, Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.8.4 By Application, Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.9 India
8.9.1 India Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.9.2 By Company, India Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.9.3 By Type, India Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.9.4 By Application, India Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.10 Middle East & Asia
8.10.1 Middle East & Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size, 2018-2029
8.10.2 By Company, Middle East & Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2018-2023
8.10.3 By Type, Middle East & Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
8.10.4 By Application, Middle East & Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share, 2022 VS 2029
9 Global Manufacturers Profile
9.1 Merck KGaA
9.1.1 Merck KGaA Company Information, Head Office, Market Area and Industry Position
9.1.2 Merck KGaA Company Profile and Main Business
9.1.3 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.1.4 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.1.5 Merck KGaA Recent Developments
9.2 Sanofi SA
9.2.1 Sanofi SA Company Information, Head Office, Market Area and Industry Position
9.2.2 Sanofi SA Company Profile and Main Business
9.2.3 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.2.4 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.2.5 Sanofi SA Recent Developments
9.3 Novartis AG
9.3.1 Novartis AG Company Information, Head Office, Market Area and Industry Position
9.3.2 Novartis AG Company Profile and Main Business
9.3.3 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.3.4 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.3.5 Novartis AG Recent Developments
9.4 Bristol Myers Squibb
9.4.1 Bristol Myers Squibb Company Information, Head Office, Market Area and Industry Position
9.4.2 Bristol Myers Squibb Company Profile and Main Business
9.4.3 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.4.4 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.4.5 Bristol Myers Squibb Recent Developments
9.5 Pfizer
9.5.1 Pfizer Company Information, Head Office, Market Area and Industry Position
9.5.2 Pfizer Company Profile and Main Business
9.5.3 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.5.4 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.5.5 Pfizer Recent Developments
9.6 Roche Holding AG
9.6.1 Roche Holding AG Company Information, Head Office, Market Area and Industry Position
9.6.2 Roche Holding AG Company Profile and Main Business
9.6.3 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.6.4 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.6.5 Roche Holding AG Recent Developments
9.7 Johnson & Johnson
9.7.1 Johnson & Johnson Company Information, Head Office, Market Area and Industry Position
9.7.2 Johnson & Johnson Company Profile and Main Business
9.7.3 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.7.4 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.7.5 Johnson & Johnson Recent Developments
9.8 Eli Lilly and Company
9.8.1 Eli Lilly and Company Company Information, Head Office, Market Area and Industry Position
9.8.2 Eli Lilly and Company Company Profile and Main Business
9.8.3 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.8.4 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.8.5 Eli Lilly and Company Recent Developments
9.9 Abbott Laboratories
9.9.1 Abbott Laboratories Company Information, Head Office, Market Area and Industry Position
9.9.2 Abbott Laboratories Company Profile and Main Business
9.9.3 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.9.4 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.9.5 Abbott Laboratories Recent Developments
9.10 Takeda Pharmaceutical Company
9.10.1 Takeda Pharmaceutical Company Company Information, Head Office, Market Area and Industry Position
9.10.2 Takeda Pharmaceutical Company Company Profile and Main Business
9.10.3 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Models, Specifications and Application
9.10.4 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue and Gross Margin, 2018-2023
9.10.5 Takeda Pharmaceutical Company Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Research Methodology:
Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|